Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anke Vennegoor

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stoppedTheo Rispens, Anke Vennegoor, Gert Jan Wolbink, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2015
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathyAnke Vennegoor, Johannis A van Rossum, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2011
Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patientsImmy A Ketelslegers, Piet W Modderman, Anke Vennegoor, et al.
Journal of Neurology|April 8, 2014
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Mike P Wattjes, Anke Vennegoor, Jop Mostert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patientsJohannis A van Rossum, Anke Vennegoor, Lisanne Balk, et al.
SAGE Open Medical Case Reports|July 27, 2018
The fat embolism syndrome as a cause of paraplegiaSiert Ta Peters, Marieke J Witvliet, Anke Vennegoor, et al.
Analytical Biochemistry|January 11, 2011
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibodyTheo Rispens, Astrid van Leeuwen, Anke Vennegoor, et al.
Journal of Immunological Methods|November 27, 2013
The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISAMarleen J A Koel-Simmelink, Anke Vennegoor, Joep Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 24, 2017
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrationsZoé LE van Kempen, Cyra E Leurs, Anke Vennegoor, et al.
Annals of Neurology|July 28, 2010
Natalizumab drug holiday in multiple sclerosis: poorly toleratedJoep Killestein, Anke Vennegoor, Eva M Strijbis, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2011
Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stoppedTheo Rispens, Anke Vennegoor, Gert Jan Wolbink, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2015
Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathyAnke Vennegoor, Johannis A van Rossum, Chris H Polman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2011
Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patientsImmy A Ketelslegers, Piet W Modderman, Anke Vennegoor, et al.
Journal of Neurology|April 8, 2014
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?Mike P Wattjes, Anke Vennegoor, Jop Mostert, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 6, 2013
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patientsJohannis A van Rossum, Anke Vennegoor, Lisanne Balk, et al.
SAGE Open Medical Case Reports|July 27, 2018
The fat embolism syndrome as a cause of paraplegiaSiert Ta Peters, Marieke J Witvliet, Anke Vennegoor, et al.
Analytical Biochemistry|January 11, 2011
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibodyTheo Rispens, Astrid van Leeuwen, Anke Vennegoor, et al.
Journal of Immunological Methods|November 27, 2013
The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISAMarleen J A Koel-Simmelink, Anke Vennegoor, Joep Killestein, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 24, 2017
Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrationsZoé LE van Kempen, Cyra E Leurs, Anke Vennegoor, et al.
Annals of Neurology|July 28, 2010
Natalizumab drug holiday in multiple sclerosis: poorly toleratedJoep Killestein, Anke Vennegoor, Eva M Strijbis, et al.
Pageof 3